Know Cancer

or
forgot password

A Phase II Study o the Adjuvant Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFR-425) Monoclonal Antibody Radiolabeled With I-125 for High Grade Gliomas


Phase 2
18 Years
N/A
Not Enrolling
Both
Gliomas

Thank you

Trial Information

A Phase II Study o the Adjuvant Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFR-425) Monoclonal Antibody Radiolabeled With I-125 for High Grade Gliomas


Inclusion Criteria:



- all cases above 18 years of age

Exclusion Criteria:

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

survival

Outcome Time Frame:

more than a year

Safety Issue:

Yes

Authority:

United States: Food and Drug Administration

Study ID:

12555

NCT ID:

NCT00589706

Start Date:

January 1985

Completion Date:

December 2012

Related Keywords:

  • Gliomas
  • high grade gliomas of the brain
  • anti-body treatment
  • survival
  • Glioma

Name

Location

Hahneman HospitalPhiladelphia, Pennsylvania  19102